Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Gene Type Associated with Higher Risk of Celiac Disease

By BiotechDaily International staff writers
Posted on 10 Jul 2014
Researcher have found that children born with 2 copies of a high-risk variant in a specific group of genes confers 26% chance of developing celiac disease autoimmunity (CDA), an early sign of celiac disease (CD), by age 5. They also found a higher celiac risk in Sweden than in the three other studied countries, even with the same genetic risk factors.

The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.

“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).

Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.

Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.

The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.

The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.

Related Links:

National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.